FGL Peptide — Deep Research (Cognitive & Nootropic)

Published · Researched 2026-09-21

Research file written 2026-09-21. Social-first methodology: community sources weighted before vendor pages.

1. Overview

FGL is a 15-amino-acid peptide derived from the neural cell adhesion molecule (NCAM) — specifically an FGFR-binding loop motif — molecular weight ~1649.8 g/mol, formula C₇₁H₁₁₆N₂₀O₂₅, CAS 499993-62-3 (Umbrella Labs spec table; also catalogued as HY-P3281). In preclinical research it is studied for promoting long-term potentiation (LTP), synaptic plasticity, AMPA-receptor delivery, and protection against amyloid-beta toxicity in rodent and cell-culture models. It is one of the most mechanistically interesting — and least human-tested — compounds in this category: no human studies, no human efficacy or safety data, no established dosing (Paragon Sports Medicine research summary).

Community presence is minimal: the anecdote trail is centered on old Longecity threads (2013–2014 era), where one user reported easier learning and a mood lift after roughly 10 days at a self-reported 250 mcg twice daily — an anecdote, not guidance. A secondary review noted it could find only one meaningful biohacker testimonial. The June-2026 GitHub hukus/llimitless scan does not place FGL among the strong anecdote nodes.

2. Social standing

A niche-of-a-niche. Practically the entire community record is:

• Longecity (2013–2014): the "FGL peptide experiences/info" thread and the older "NCAM-derived FGF peptide sparks synaptic plasticity" thread. One user-reported benefit (learning ease, mood lift, ~10 days, 250 mcg 2×/day self-reported); mechanism discussion (NCAM/FGFR, AMPA receptor delivery, LTP, rodent memory results) outweighs experience reports by a wide margin.
• Jay Campbell blog ("FGL: The Brain Power Peptide"): a vendor-adjacent explainer — proves the compound has a name in the wider biohacker media ecosystem, not community endorsement.
• Looksmax "peptide gigathread": lists FGL among frontier compounds — name recognition only.
• Recurring community position: "interesting mechanism, no human data" — nobody claims validated benefit.
• Overhyped warnings: vendor marketing that frames FGL as a wound-healing/angiogenesis peptide (Umbrella Labs' "What is FGL?" copy describes fibrinogen-derived immune/angiogenesis activity, which does not match the NCAM-derived 15-mer's published research profile) — sloppy vendor copy that undermines confidence in what is actually in the vial. Treat the product-description mismatch as a quality red flag.

3. Social validation — Tier 3 / UNVALIDATED — included for comparison, low community signal

• Longecity experience thread (2013–2014): one user-reported benefit (easier learning, mood lift after ~10 days) plus dose folklore (250 mcg 2×/day self-reported). Proves at least one self-experimenter tried it and reported an effect — a single anecdote, not evidence.
• Longecity mechanism thread: proves the preclinical story (LTP, synaptic plasticity, rodent memory) is understood by the community. Proves mechanism interest, not human efficacy.
• Paragon Sports Medicine research summary (FDA status: not approved, preclinical only, Phase I needed): proves an independent medical publisher classifies it as a preclinical research compound with no human data. Proves the absence of human evidence is a documented fact, not an oversight.
• Vendor product pages (Umbrella Labs — 2/5/10 mg vials, ≥99% LC-MS claim, COA archive): prove commercial availability in standard vial formats.
• Missing: no named Facebook Group posts, no Threads owner content, no Instagram owner content, no 2024–2026-era self-reports found this round. The anecdote trail is essentially frozen in 2014.

4. Key specs table

5. Pricing (observed 2026-09-21)

Marketplace used range: not observed — report honestly, no used-market data found. Street pricing for the nootropic-vendor 10 mg vial was not observed this round; the lab-grade reference price (£347/10 mg) is the only hard 2026 number and is not a street price. Do not invent a street price.

6. What's included / what's needed

• Lyophilized vial ships as powder; reconstitution solution typically sold separately.
• No reconstitution or dosing protocol exists in any research literature; all use protocols are community folklore.

7. Support reality

• COA culture: Umbrella Labs advertises a COA archive and ≥99% LC-MS purity; batch-tracking icons are marketing rather than published certificates at observation.
• Vendor copy red flag: the "What is FGL?" description on the main vendor page describes a fibrinogen-derived angiogenesis/immune peptide, which does not match the NCAM-derived 15-mer's published profile — buyers should treat this as evidence the vendor's marketing was not written against the actual molecule.
• Gray-market risk: research-use-only labeling everywhere; no pharmacy QA chain.

8. Community verdict

FGL is the category's museum piece: a beautiful preclinical mechanism (LTP, synaptic plasticity, neuroprotection in rodents) with one decade-old anecdote and no human data whatsoever. The community stopped talking about it around 2014 and never came back. Interesting to researchers; not a product with a user base.

9. Regulatory & safety status

• USA/EU: not FDA or EMA approved; preclinical development stage; "Phase I human studies needed for safety determination" per Paragon Sports Medicine. Sold as a research chemical not for human use.
• WADA: status unclear for competitive sports; limited detection methods available (Paragon).
• Community-reported side effects: none documented in this session's extraction (essentially no review footprint).

Images

7/8 views present in img/: fgl-peptide-hero.jpg, fgl-peptide-side.jpg, fgl-peptide-rear.jpg, fgl-peptide-top.jpg, fgl-peptide-detail.jpg, fgl-peptide-scale.jpg, fgl-peptide-box.jpg. All verified valid JPEGs. Missing views: in-use/owner photo — no distinct real photo found for this view; named honestly.

Not medical advice. This is community research, not a recommendation. FGL is an unapproved research chemical with no human safety data; it is not for human use. Talk to a clinician before considering any peptide.

Named sources

• Umbrella Labs spec table — Identity: 15-aa NCAM-derived FGFR-binding loop peptide
• Umbrella Labs listing — Form: Lyophilized powder vials (2/5/10 mg)
• Umbrella Labs — Purity claim: ≥99% (LC-MS) — vendor claim
• Primary literature — Mechanism (preclinical): FGFR activation; LTP/synaptic plasticity; AMPA-receptor delivery; amyloid-beta protection
• Longecity summaries — Mechanism (preclinical): FGFR activation; LTP/synaptic plasticity; AMPA-receptor delivery; amyloid-beta protection
• Paragon Sports Medicine — Human trials: None.
• Longecity — Community-cited dose: 250 mcg 2×/day (one user's self-report, 2014) — not medical guidance, n=1 anecdote
• bioscience.co.uk — [Glp1]-FGL peptide (acetate) 10 mg, lab-grade reference | **£347.00** (99.86% purity) | MedChemExpress via bioscience.co.uk, observed 2026-09-21 | | Production-cost context | ~$2/mg cost basis noted by a Longecity user (~$20/10 mg to manufacture) | Longecity… (2026-09-21)
• Jay Campbell blog — a vendor-adjacent explainer — proves the compound has a name in the wider biohacker media ecosystem, not community endorsement.
• Looksmax "peptide gigathread" — lists FGL among frontier compounds — name recognition only.
• Longecity experience thread (2013–2014) — one user-reported benefit (easier learning, mood lift after ~10 days) plus dose folklore (250 mcg 2×/day self-reported). (2013–2014)
• Longecity mechanism thread — proves the preclinical story (LTP, synaptic plasticity, rodent memory) is understood by the community.
• Paragon — - **USA/EU:** **not FDA or EMA approved**; preclinical development stage; "Phase I human studies needed for safety determination" per Paragon Sports Medicine.
• Community — | Community-cited dose | 250 mcg 2×/day (one user's self-report, 2014) | Longecity — **not medical guidance, n=1 anecdote** | (2014)

Source URLs were not recorded for these references.